Purpose
In the present study, we aimed to establish a liquid biopsy-based monitoring method using peripheral blood cell-free DNA (cfDNA) for patients with cervical cancer who underwent radical radiotherapy (RT).
Materials and Methods
Twenty-five patients with cervical cancer were prospectively recruited and treated with external beam RT and brachytherapy. In all patients, except one, chemotherapy was administered concurrently during RT. Whole peripheral blood samples were obtained at least twice from each patient. We performed next-generation sequencing (NGS) for the target-captured libraries (67 oncogenes and human papillomavirus [HPV] type 16/18) using 64 plasma cfDNA samples from the 25 participants. The ratio of HPV cfDNA and the variant allele frequency (VAF) in cfDNA was calculated, and their dynamic changes were monitored. The median follow-up duration was 25.4 months.
Results
In total, we identified 21,866 cfDNA variants. ARID1A and frameshift variants occupied the largest portion of altered genes and HIGH-grade variant types, respectively. In most cases, tumor shrinkage was followed by a decrease in the HPV ratio; however, an increase in HPV ratio indicated distant metastasis, despite the reduced tumor size. The initial HPV ratio reflecting the tumor burden was likely associated with treatment outcomes (p = 0.16). We did not determine a role for serial changes in the VAF in cfDNA.
Conclusion
Our findings suggest that the HPV cfDNA ratio, calculated after targeted NGS, may be valuable for monitoring and predicting treatment responses. Accordingly, further validation of these findings is warranted.
Citations
Citations to this article as recorded by
Circulating cell-free DNA as a diagnostic and prognostic marker for cervical cancer Preetiparna Parida, Gayathri Baburaj, Mahadev Rao, Shirley Lewis, Rama Rao Damerla International Journal of Gynecological Cancer.2024; 34(2): 307. CrossRef
Prognostic value of circulating short-length DNA fragments in unresected glioblastoma patients Arthur Daban, Ludivine Beaussire-Trouvay, Émilie Lévêque, Cristina Alexandru, Isabelle Tennevet, Olivier Langlois, Ovidiu Veresezan, Florent Marguet, Florian Clatot, Frédéric Di Fiore, Nasrin Sarafan-Vasseur, Maxime Fontanilles Translational Oncology.2024; 42: 101897. CrossRef
Cervical Cancer Genetic Profile through Circulating Tumor DNA: What Can We Learn from Blood? Sevastiani Antonouli, Valentina Di Nisio, Nikoletta Daponte, Athina-Ioanna Daponte, Alexandros Daponte Biomolecules.2024; 14(7): 825. CrossRef
High throughput sequencing technology and its clinical application in circulating tumor DNA detection in patients with tumors. Chonghe Xu, Dangui Zhou, Mei Zhu Investigación Clínica.2024; 65(4): 476. CrossRef
Semin Cho, Eunjeong Kang, Ji Eun Kim, U Kang, Hee Gyung Kang, Minsu Park, Kwangsoo Kim, Dong Ki Kim, Kwon Wook Joo, Yon Su Kim, Hyung-Jin Yoon, Hajeong Lee
Cancer Res Treat. 2021;53(4):1015-1023. Published online January 18, 2021
Purpose
Acute kidney injury (AKI) in cancer patients is associated with increased morbidity and mortality. The incidence of AKI in lung cancer seems to be relatively higher compared with other solid organ malignancies, although its impact on patient outcomes remains unclear.
Materials and Methods
The patients newly diagnosed with lung cancer from 2004 to 2013 were enrolled in this retrospective cohort study. The patients were categorized according to the presence and severity of AKI. We compared all-cause mortality and long-term renal outcome according to AKI stage.
Results
A total of 3,202 patients were included in the final analysis. AKI occurred in 1,783 (55.7%) patients during the follow-up period, with the majority having mild AKI stage 1 (75.8%). During the follow-up of 2.6±2.2 years, total 1,251 patients (53.7%) were died and 5-year survival rate was 46.9%. We found that both AKI development and severity were independent risk factors for all-cause mortality in lung cancer patients, even after adjustment for lung cancer-specific variables including the stage or pathological type. In addition, patients suffered from more severe AKI tend to encounter de novo chronic kidney disease development, worsening kidney function, and end-stage kidney disease progression.
Conclusion
In this study, more than half of the lung cancer patients experienced AKI during their diagnosis and treatment period. Moreover, AKI occurrence and more advanced AKI were associated with a higher mortality risk and adverse kidney outcomes.
Citations
Citations to this article as recorded by
Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials Isabela Gonçalves Lima, Isabele Benck Usiro Cabral da Silva, Vitória Carpentieri Pípolo, Vinicius Daher Alvares Delfino, Paulo Roberto Bignardi Immunopharmacology and Immunotoxicology.2024; 46(4): 470. CrossRef
Prevalence of kidney disease in patients with different types of cancer or hematological malignancies: a cross-sectional study Feng Wu, Shiyuan Wang, Jialing Zhang, Peixin Wang, Aihua Zhang International Urology and Nephrology.2024; 56(12): 3835. CrossRef
Protective effect of reduced glutathione on acute kidney injury in lung cancer patients treated with cisplatin: a retrospective cohort study Ying Huang, Yang Li, Xialian Xu, Jie Teng, Xiaoqiang Ding, Jiarui Xu Renal Failure.2024;[Epub] CrossRef
Association between renal dysfunction and outcomes of lung cancer: A systematic review and meta‑analysis Huijuan Qian, Si Li, Ziyun Hu Oncology Letters.2024;[Epub] CrossRef
Association and prediction of red blood cell distribution width to albumin ratio in all-cause mortality of acute kidney injury in critically ill patients Chen Gao, Longkai Peng Frontiers in Medicine.2023;[Epub] CrossRef
Point of care ultrasonography in onco-nephrology: A stride toward better physical examination Bhavna Bhasin-Chhabra, Abhilash Koratala World Journal of Nephrology.2023; 12(2): 29. CrossRef
Protocolo diagnóstico y tratamiento de la nefropatía en los pacientes con neoplasia sólida Rodríguez Doyágüez, M.P. Morán Magro, C.M. Durán López, P. Martínez Miguel Medicine - Programa de Formación Médica Continuada Acreditado.2023; 13(82): 4870. CrossRef
Purpose
We investigated B-cell lymphoma 2 (BCL2) regulation across DNA, RNA, protein, and methylation status according to molecular subtype of breast cancer using The Cancer Genome Atlas (TCGA) database.
Materials and Methods
We analyzed clinical and biological data on 1,096 breast cancers from the TCGA database. Biological data included reverse phase protein array (RPPA), mRNA sequencing (mRNA-seq), mRNA microarray, methylation, copy number alteration linear, copy number alteration nonlinear, and mutation data.
Results
The luminal A and luminal B subtypes showed upregulated expression of RPPA and mRNAseq and hypomethylation compared to the human epidermal growth factor receptor 2 (HER2) and triple-negative subtypes (all p < 0.001). No mutations were found in any subjects. High mRNA-seq and high RPPA were strongly associated with positive estrogen receptor, positive progesterone receptor (all p < 0.001), and negative HER2 (p < 0.001 and p=0.002, respectively). Correlation analysis revealed a strong positive correlation between protein and mRNA levels and a strong negative correlation between methylation and protein and mRNA levels (all p < 0.001). The high BCL2 group showed superior overall survival compared to the low BCL2 group (p=0.006).
Conclusion
The regulation of BCL2 was mainly associated with methylation across the molecular subtypes of breast cancer, and luminal A and luminal B subtypes showed upregulated expression of BCL2 protein, mRNA, and hypomethylation. Although copy number alteration may have played a minor role, mutation status was not related to BCL2 regulation. Upregulation of BCL2 was associated with superior prognosis than downregulation of BCL2.
Citations
Citations to this article as recorded by
AL16ALA-SOD2 polymorphism predicts recurrence risk of breast cancer in patients treated with adjuvant tamoxifen Maiquidieli Dal Berto, Laura Martin Manfroi, Aniúsca Vieira dos Santos, Giovana Tavares dos Santos, Gabriela Krüger da Costa, Camila Macedo Boaro, Péttala Rigon, Rafael José Vargas Alves, Claudia Giuliano Bica Advances in Cancer Biology - Metastasis.2023; 8: 100108. CrossRef
Clinicopathological features and prognosis of patients with HER2-low breast cancer Xin Yang, Yao Li, Xu lu, Xiaotian Ren, Bin Hua BMC Cancer.2023;[Epub] CrossRef
Development of a prediction model for radiotherapy response among patients with head and neck squamous cell carcinoma based on the tumor immune microenvironment and hypoxia signature Guang‐Li Zhu, Kai‐Bin Yang, Cheng Xu, Rui‐Jia Feng, Wen‐Fei Li, Jun Ma Cancer Medicine.2022; 11(23): 4673. CrossRef
Significance of Bcl-2 expression in breast cancer Nitika Kumari, Natarajan Suresh, Josephine A. Biomedicine.2022; 42(4): 775. CrossRef
Detecting the expression of HRs and BCL2 via IHC can help identify luminal A-like subtypes of triple-positive breast cancers Yingying Xu, Yonghao Liang, Guanghao Yin Clinical and Translational Oncology.2022; 25(4): 1024. CrossRef
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft Lorena Landuzzi, Arianna Palladini, Claudio Ceccarelli, Sofia Asioli, Giordano Nicoletti, Veronica Giusti, Francesca Ruzzi, Marianna L. Ianzano, Laura Scalambra, Roberta Laranga, Tania Balboni, Maddalena Arigoni, Martina Olivero, Raffaele A. Calogero, Car Scientific Reports.2021;[Epub] CrossRef
Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer Ki-Tae Hwang, Young A. Kim, Jongjin Kim, Hyeon Jeong Oh, Jeong Hwan Park, In Sil Choi, Jin Hyun Park, Sohee Oh, Ajung Chu, Jong Yoon Lee, Kyu Ri Hwang Scientific Reports.2021;[Epub] CrossRef
p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study Alessandra Fabi, Marcella Mottolese, Anna Di Benedetto, Francesca Sperati, Cristiana Ercolani, Simonetta Buglioni, Cecilia Nisticò, Gianluigi Ferretti, Patrizia Vici, Letizia Perracchio, Paola Malaguti, Michelangelo Russillo, Claudio Botti, Edoardo Pescar Clinical Breast Cancer.2020; 20(6): e761. CrossRef
Methylation of the NT5E Gene Is Associated with Poor Prognostic Factors in Breast Cancer Young Ju Jeong, Hoon Kyu Oh, Hye Ryeon Choi, Sung Hwan Park Diagnostics.2020; 10(11): 939. CrossRef
Differential responses of epithelial cells from urinary and biliary tract to eggs of Schistosoma haematobium and S. mansoni Rafael Nacif-Pimenta, Alessandra da Silva Orfanó, Ilana A. Mosley, Shannon E. Karinshak, Kenji Ishida, Victoria H. Mann, Paulo Marcos Zech Coelho, José M. Correia da Costa, Michael H. Hsieh, Paul J. Brindley, Gabriel Rinaldi Scientific Reports.2019;[Epub] CrossRef
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer Hariprasad Thangavel, Carmine De Angelis, Suhas Vasaikar, Raksha Bhat, Mohit Kumar Jolly, Chandandeep Nagi, Chad J. Creighton, Fengju Chen, Lacey E. Dobrolecki, Jason T. George, Tanya Kumar, Noor Mazin Abdulkareem, Sufeng Mao, Agostina Nardone, Mothaffar Journal of Clinical Medicine.2019; 8(11): 1772. CrossRef
BCL2L12: a multiply spliced gene with independent prognostic significance in breast cancer Athina Kladi-Skandali, Diamantis C. Sideris, Andreas Scorilas Clinical Chemistry and Laboratory Medicine (CCLM).2018; 57(2): 276. CrossRef